NCT07136077View on ClinicalTrials.gov

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 18, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2028

Conditions
Minimal Residual DiseaseAdjuvant ChemotherapyColorectal CancerFruquintinibTislelizumabctDNA
Interventions
DRUG

Tislelizumab

Given by IV

DRUG

Fruquintinib

Give by PO

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

BeiGene
All Listed Sponsors
collaborator

BeiGene

INDUSTRY

collaborator

Takeda Pharmaceutical Co. Limited

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER